Director Colin Walsh's Amended Form 4 Reveals $12.5M Purchase and Previously Undisclosed Equity Swaps
ATTO sits 28% above its 52-week low of $16.15 on light trading volume (0.2× avg).
Summary
Amended Form 4 reveals Director Colin Walsh's total purchases were $12.5 million (not $8.5M as originally filed), plus previously undisclosed equity swap positions of 105,807 shares.
Key Events · Ownership and Investor Activity · ATTO
-
Amended Purchase Total: $12.5M
Director Colin Walsh's open market purchases totaled $12,533,074 across 8 transactions at $17.00–$21.27 per share, up from the $8.5M originally reported.
-
Previously Undisclosed Equity Swaps
The amendment discloses 105,807 shares of long equity swap positions established on August 5, 2026, which were inadvertently omitted from the original Form 4.
-
Concurrent Sale of $2.25M
Walsh also sold 105,807 shares for $2,251,658 at $20.84–$22.19 per share on August 5, 2026, resulting in a net buy of approximately $10.3 million.
-
Preferred Stock Conversion Correction
The filing corrects an administrative error in the Form 3 regarding the number of common shares issuable upon conversion of Series B and Series C Preferred Stock.
Analysis · ATTO · Life Sciences
This amendment to Colin Walsh's August 13 Form 4 discloses material new information: the director's total open market purchases were $12.5 million, not the $8.5 million originally reported, and 105,807 shares of equity swap positions were inadvertently omitted. The filing also corrects an administrative error in the Form 3 regarding preferred stock conversion counts. The net effect is a larger-than-previously-known accumulation by a director, alongside a $2.25 million sale, which strengthens the insider accumulation signal for Attovia Therapeutics.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ATTO was trading at $20.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $943.5M. The 52-week trading range was $16.15 to $24.32. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.